Nostopharma LLC
Rockville, MD
- UEI
- FKVPNPQK64H8
- CAGE
- 7ZZH1
- Primary NAICS
- 541713 Research and Development in Nanotechnology
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Partnership or Limited Liability Partnership
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 5 Greenlane Ct, Rockville, MD 20854, USA
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Prevention of heterotopic ossification with localized delivery of arsenic trioxide loaded nanoparticles as a novel… | National Center for Advancing Translational Sciences | $815,584 | |
| Sbir phase II: improved drug delivery platforms for localized and sustained drug deposition for traumatic injuries… | National Science Foundation | $1,016,000 | |
| Small molecules combination therapy using polypharmacology approach as a novel treatment paradigm for rare bone… | National Center for Advancing Translational Sciences | $681,985 | |
| Sttr phase i: improved drug delivery platforms for localized and sustained drug deposition for traumatic injuries -the… | National Science Foundation | $256,000 |
About Nostopharma LLC
Nostopharma LLC is a Rockville, Maryland-based small business registered in SAM.gov as a woman-owned limited liability company, specializing in advanced nanomedicine and drug delivery technologies. The company focuses on developing innovative pharmaceutical solutions for rare genetic diseases and trauma-related medical conditions, with a particular emphasis on creating localized, targeted drug delivery platforms using nanoparticle technologies. Nostopharma is certified as a small disadvantaged business and operates as a for-profit organization with expertise in developing advanced drug formulations that can address complex medical challenges.
The company has received multiple federal grant awards from agencies like the National Center for Advancing Translational Sciences (NCATS) and the National Science Foundation (NSF), focusing on developing specialized drug delivery systems for rare bone diseases and traumatic injuries. Their grant-funded research has centered on creating sustained-release, biodegradable nanoparticle drug delivery platforms that target specific medical conditions, including Fibrodysplasia Ossificans Progressiva (FOP), Progressive Osseous Heteroplasia (POH), and soft tissue trauma complications. Specific projects have involved developing innovative treatments using Hedgehog pathway inhibitors like arsenic trioxide, encapsulated in immunomodulatory nanoparticles to enable localized drug delivery with reduced systemic toxicity. The grants range from Small Business Innovation Research (SBIR) Phase I and II awards to Small Business Technology Transfer (STTR) project grants, with award amounts between $256,000 and $815,584, demonstrating the company's consistent success in securing competitive federal research funding for cutting-edge medical technologies.
Quick answers
What is Nostopharma LLC's UEI?
Nostopharma LLC's Unique Entity ID (UEI) in SAM.gov is FKVPNPQK64H8.
What is Nostopharma LLC's CAGE code?
Nostopharma LLC's CAGE code is 7ZZH1.
What is Nostopharma LLC's primary NAICS code?
Nostopharma LLC's primary NAICS code is 541713 (Research and Development in Nanotechnology).
Where is Nostopharma LLC located?
Nostopharma LLC's physical address in SAM.gov is 5 Greenlane Ct, Rockville, MD 20854, USA.
Is Nostopharma LLC registered in SAM.gov?
Yes. Nostopharma LLC's SAM.gov registration is active through May 17, 2027.
What is Nostopharma LLC's most recent federal award?
Nostopharma LLC's most recent federal grant award is Prevention of heterotopic ossification with localized delivery of arsenic trioxide loaded nanoparticles as a novel… (R21TR005159), from National Center for Advancing Translational Sciences, on July 3, 2025.
On GovTribe
See Nostopharma LLC's full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors